Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : KGK Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2023
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : KGK Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Recipient : Wellbeing Digital Sciences
Deal Size : Undisclosed
Deal Type : Agreement
Details : The pioneering Phase II clinical trial is the first human research investigating the potential of a microdose of psilocybin to improve behavioural and cognitive symptoms associated with Fragile X syndrome.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
November 17, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Recipient : Wellbeing Digital Sciences
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Psilocybine
Therapeutic Area : Endocrinology
Study Phase : Phase I
Recipient : Wellbeing Digital Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The psilocybin 1.5mg capsules are available for potential therapeutic use in non-ASD clinical trials, including but not limited to diabetes, heart disease, cancer, and post-traumatic stress disorder.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Recipient : Wellbeing Digital Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism
Details : The results exceeded all expectations with the findings that a very low dose of the Company’s proprietary PLZ-1013 (psilocybin) significantly modulated behavioural and cognitive defects, such as recognition memory, in a genetic model of fragile X syndr...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 16, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome
Details : Psilocybin has the capacity to influence cognition and behaviour as well as modulate the immune system and neural signaling pathways. Likewise, psilocybin is non-toxic and is not expected to have adverse side effects in humans.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 26, 2021
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nova Mentis Files Genetic Neuroinflammatory Disease Patent
Details : Nova Mentis has filed a genetic neuroinflammatory disease patent which describes a diagnostic/therapeutic combination of mRNA molecules that encode proteins involved in the development of neurogenerative diseases, including fragile X syndrome and autism ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 11, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Approves Nova Mentis Orphan Drug Application
Details : The attainment of Orphan Drug status in both the U.S. and Europe is significant milestone towards launch of psilocybin FXS phase 2 clinical studies. Psilocybin drug used to treat patients with fragile X syndrome most of autism spectrum disorder.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 11, 2021
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
